AU
UK
CA
NZ
IND
US
Basel Medical Group (NASDAQ: BMGL) announced that it will implement a 1-for-12 reverse stock split effective June 22, 2026.
CervoMed (NASDAQ: CRVO) announced a private placement expected to generate approximately $10.5 million in upfront gross proceeds.
Rafael Holdings (NYSE: RFL) announced the successful completion of the Last Patient Last Visit milestone for the final 96-week treatment period in its global Phase 3 TransportNPC clinical trial.
Polyrizon (NASDAQ: PLRZ) announced that the European Patent Office published its patent application covering the company's Trap & Target mucoadhesive nasal-delivery technology.
Dianthus Therapeutics (NASDAQ: DNTH) is in focus following a major development in the neuro-immunology sector. Sanofi (NASDAQ: SNY) announced the termination of its Phase 3 MOBILIZE trial evaluating riliprubart after the study failed to demonstrate sufficient clinical efficacy.
Investor Sentiment Diverges
Technical Anomalies and Market Reactions
Market Dynamics and Illiquidity
Market Dynamics and Investor Sentiment
Please wait processing your request...